Comprehensive analysis of MHC-class I-restricted cancer antigen peptides
| Project/Area Number |
25830108
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor diagnostics
|
|---|
| Research Institution | National Cancer Center Japan |
|---|
Principal Investigator |
NARUMI Kenta 独立行政法人国立がん研究センター, その他部局等, 研究員 (10534258)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | ペプチドワクチン / がん抗原 / 循環血中腫瘍細胞 / がんワクチン療法 / オーダーメイド治療 |
|---|
| Outline of Final Research Achievements |
Here we reported an acid-stripping-mediated comprehensive analysis method of MHC class I-restricted cancer antigen peptides. We added five HLA-A24-restricted Glypican3-related peptides peptides to the HLA-A24-expressing cells, following acid-stripping and ultrafiltration. The filtrates were analyzed by 2DICAL. It was revealed that only the peptide which had the strongest binding affinity against the HLA-A24 molecules was detected in the filtrates. This finding indicated that acid-stripping and 2DICAL analysis was a useful method to detect HLA-A24-binding peptides. This method may be applicable to the comprehensive screening of cancer antigen using circulating tumor cells.
|
Report
(3 results)
Research Products
(6 results)
